KPTI - Karyopharm Therapeutics GAAP EPS of -$0.30 misses by $0.05 revenue of $36M misses by $1.4M
2023-11-02 07:33:14 ET
More on Karyopharm Therapeutics
- Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away
- Karyopharm Therapeutics Q3 2023 Earnings Preview
- Karyopharm, Bristol Myers to evaluate drug combination for treatment of multiple myeloma
- Seeking Alpha’s Quant Rating on Karyopharm Therapeutics
- Historical earnings data for Karyopharm Therapeutics
For further details see:
Karyopharm Therapeutics GAAP EPS of -$0.30 misses by $0.05, revenue of $36M misses by $1.4M